VJHemOnc is committed to improving our service to you

ASH 2019 | Key amyloidosis data from ASH 2019

VJHemOnc is committed to improving our service to you

Morie Gertz

Morie Gertz, MD, MACP, Mayo Clinic College of Medicine, Rochester, MN, highlights key amyloidosis data from the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL. In particular, the phase III trial of ixazomib, dexamethasone, and cyclophosphamide in patients with light chain (AL) amyloidosis.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter